Navigation Links
Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital
Date:5/15/2009

LA JOLLA, Calif., May 15 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights jointly owned by Children's Hospital Boston and Massachusetts General Hospital. This intellectual property covers compositions and methods for supporting hematopoietic stem cells. These proprietary technologies developed by Leonard Zon, M.D., director of the Stem Cell Program at Children's Hospital Boston and a scientific founder of Fate Therapeutics, expand the Company's broad intellectual property portfolio for modulating the activity and state of stem cells. Fate Therapeutics is utilizing its adult stem cell biology engine and induced pluripotent stem (iPS) cell technology platform to develop Stem Cell Modulators (SCMs) - small molecules and biologics that guide cell fate for therapeutic purposes.

"Over the past two years, Fate Therapeutics has amassed extensive intellectual property assets as a foundation for our adult stem cell biology engine," said Paul Grayson, president and CEO of Fate Therapeutics. "The agreement we signed today with Children's Hospital and the technologies associated with it continue to expand our engine and accelerate the Company's core mission to develop small molecules and biologics that modulate adult stem cells for regenerative medicine."

The exclusive rights acquired today will be incorporated into Fate Therapeutics' growing adult stem cell biology engine, which also includes exclusive rights to the pioneering work of the Company's scientific founders and other leaders in the field. Adult stem cells are naturally-occurring cells found in almost all tissues or organs in the body and are primarily responsible for maintaining and repairing their native tissue. An adult stem cell has unique properties
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015  For about a century, a known ... to utilize and catabolize glucose at a high ... called the ,Warburg phenomenon", that is an increased ... presence, leading to enhanced lactate generation. Even under ... glucose fermentation. A variety of such abnormalities have ...
(Date:4/27/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the year ended December 31, 2014. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... not provide the outcome management and investors had ... iCo Therapeutics", said Andrew Rae , President ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 /PRNewswire/ ... para un nuevo receptor utilizando tecnología de descubrimiento de ... cubierta en el tratamiento de millones de pacientes con ... hoy que ha recibido una patente en Europa titulada ... descubrimiento de Molecular Health de que EPHB4 es un ...
(Date:4/27/2015)... Dr. Robert Hanzlik, whose groundbreaking research into ... for advancing the creation of safer pharmaceuticals, will be ... , the second-largest private, nonprofit university in California. , ... at the University of Kansas School of Pharmacy who ... 5 p.m. and takes place at National University’s Torrey ...
Breaking Biology Technology:Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3
... , , PRINCETON, N.J., July 24 ... companies from around the world who gather at InformexUSA 2010 will ... past, allowing them to connect more precisely with others in their ... The show opens February 16, 2010 in San Francisco, with a ...
... , SILVER SPRING, Md., July 24 ... that it will release its 2009 second quarter financial results ... , United Therapeutics Corporation will host ... a.m. Eastern Time. The teleconference is accessible by dialing ...
... ... offers Fetal Bovine Serum (FBS) originating from abattoirs located in the US, ... treatments such as heat inactivation, dialysis, or gamma irradiation are available as ... FBS for embryonic stem cell research. Each FBS order includes a ...
Cached Biology Technology:Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 2Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 3Spectrum Announces Fetal Bovine Serum Product Line 2
(Date:4/27/2015)... 2015 Profile Solutions, Inc. (OTC: PSIQ), a ... is pleased to announce that Dr Gerry Bedore ... member of its scientific advisory board. ... thought leader in technology-enhanced learning models. He was a ... published studies and books focused on online student success ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... that the effects of prion disease could be reversed ... findings support developing early treatments that aim to reduce ... with prion disease. Also, they said that their findings ... way: by analyzing their cognitive effects in prion-infected mice. ...
... autopsy data provide the strongest evidence yet that sudden infant ... a concrete biological basis. In the November 1 issue of ... brainstem ?a part of the brain that regulates breathing, blood ... SIDS. , SIDS is the leading cause of death ...
... Jude Children's Research Hospital have demonstrated in a mouse model ... that not only greatly reduces the size of the tumor, ... standard chemotherapy. The treatment also appears to be suitable for ... is simple enough for widespread use even in countries with ...
Cached Biology News:Prion disease treatable if caught early 2A potential biological cause for sudden infant death syndrome 2A potential biological cause for sudden infant death syndrome 3St. Jude announces breakthrough in eye cancer treatment 2St. Jude announces breakthrough in eye cancer treatment 3St. Jude announces breakthrough in eye cancer treatment 4
... on over 20 years of experience in ... Life Sciences, the Freedom EVO platform delivers ... according to future needs. Together with the ... is equipped to successfully operate genomics, proteomics, ...
... Use in any standard fixed-angle ... 16,000 g.,Spin- centrifuge tube filters ... within a centrifuge tube. They filter ... removal, HPLC sample preparation, removal of ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: polystyrene ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
Biology Products: